ARYX

Aryx Therapeutics I

ARYX, USA

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.

https://www.aryx.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2010-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

32.50 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-42.10 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of Aryx Therapeutics I

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2010-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2010-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2010-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2010-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.